CN113905735B - 神经激肽-1拮抗剂 - Google Patents

神经激肽-1拮抗剂 Download PDF

Info

Publication number
CN113905735B
CN113905735B CN202080040881.3A CN202080040881A CN113905735B CN 113905735 B CN113905735 B CN 113905735B CN 202080040881 A CN202080040881 A CN 202080040881A CN 113905735 B CN113905735 B CN 113905735B
Authority
CN
China
Prior art keywords
compound
alkyl
formula
hydrogen
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080040881.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN113905735A (zh
Inventor
黄建
祝令建
邹洋
唐应刚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujian Shengdi Pharmaceutical Co ltd
Jiangsu Hengrui Medicine Co Ltd
Shanghai Shengdi Pharmaceutical Co Ltd
Shanghai Senhui Medicine Co Ltd
Original Assignee
Fujian Shengdi Pharmaceutical Co ltd
Jiangsu Hengrui Medicine Co Ltd
Shanghai Shengdi Pharmaceutical Co Ltd
Shanghai Senhui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujian Shengdi Pharmaceutical Co ltd, Jiangsu Hengrui Medicine Co Ltd, Shanghai Shengdi Pharmaceutical Co Ltd, Shanghai Senhui Medicine Co Ltd filed Critical Fujian Shengdi Pharmaceutical Co ltd
Priority to CN202410285183.XA priority Critical patent/CN118324811A/zh
Publication of CN113905735A publication Critical patent/CN113905735A/zh
Application granted granted Critical
Publication of CN113905735B publication Critical patent/CN113905735B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65615—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing a spiro condensed ring system of the formula where at least one of the atoms X or Y is a hetero atom, e.g. S
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
CN202080040881.3A 2019-06-28 2020-06-28 神经激肽-1拮抗剂 Active CN113905735B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410285183.XA CN118324811A (zh) 2019-06-28 2020-06-28 神经激肽-1拮抗剂

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910572272 2019-06-28
CN2019105722721 2019-06-28
CN2019113752625 2019-12-27
CN201911375262 2019-12-27
PCT/CN2020/098460 WO2020259675A1 (zh) 2019-06-28 2020-06-28 神经激肽-1拮抗剂

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410285183.XA Division CN118324811A (zh) 2019-06-28 2020-06-28 神经激肽-1拮抗剂

Publications (2)

Publication Number Publication Date
CN113905735A CN113905735A (zh) 2022-01-07
CN113905735B true CN113905735B (zh) 2024-03-15

Family

ID=74059657

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080040881.3A Active CN113905735B (zh) 2019-06-28 2020-06-28 神经激肽-1拮抗剂
CN202410285183.XA Pending CN118324811A (zh) 2019-06-28 2020-06-28 神经激肽-1拮抗剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410285183.XA Pending CN118324811A (zh) 2019-06-28 2020-06-28 神经激肽-1拮抗剂

Country Status (11)

Country Link
US (1) US12421260B2 (https=)
EP (1) EP3991730A4 (https=)
JP (2) JP7702887B2 (https=)
KR (1) KR102940508B1 (https=)
CN (2) CN113905735B (https=)
AU (1) AU2020308397B2 (https=)
BR (1) BR112021026554A2 (https=)
CA (1) CA3144247A1 (https=)
MX (1) MX2021015827A (https=)
TW (1) TWI853965B (https=)
WO (1) WO2020259675A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021407138A1 (en) * 2020-12-25 2023-06-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Use of nk1 antagonist prodrug compound in combination with 5-ht3 receptor antagonist
CN114671913A (zh) * 2020-12-25 2022-06-28 上海盛迪医药有限公司 一种神经激肽-1拮抗剂的晶型及其制备方法
JP2025500688A (ja) * 2022-01-12 2025-01-09 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 ニューロキニン－１アンタゴニストプロドラッグ化合物の医薬組成物
CN118475589A (zh) 2022-01-12 2024-08-09 江苏恒瑞医药股份有限公司 一种神经激肽-1拮抗剂前药化合物的晶型
CN119528985A (zh) 2023-08-28 2025-02-28 科睿迪(南京)医药科技有限公司 神经激肽-1受体拮抗剂化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678317A (zh) * 2002-07-03 2005-10-05 先灵公司 用作治疗呕吐、抑郁症、焦虑症和咳嗽的神经激肽－1(nk－1)拮抗剂的1－酰氨基－4－苯基－4－苄氧基甲基－哌啶衍生物和相关化合物
CN1897942A (zh) * 2003-12-22 2007-01-17 先灵公司 药用组合物
CN102573475A (zh) * 2009-08-14 2012-07-11 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU678409B2 (en) 1992-10-28 1997-05-29 Merck Sharp & Dohme Limited 4-arylmethyloxymethyl piperidines as tachykinin antagonists
US5661162A (en) 1992-12-14 1997-08-26 Merck Sharp & Dohme Limited 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperdines as tachykinin receptor antagonists
ES2120170T3 (es) 1994-01-13 1998-10-16 Merck Sharp & Dohme Antagonistas azaciclicos gem-disustituidos de taquiquininas.
WO1998022542A2 (en) * 1996-11-08 1998-05-28 Ikonos Corporation Chemical functionalization of surfaces
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
CA3123900A1 (en) * 2011-07-28 2013-01-31 Kempharm Inc. Methylphenidate-prodrugs, processes of making and using the same
CN102775401B (zh) 2012-08-15 2015-01-07 青岛农业大学 一种美洛昔康的合成方法
CN108148060B (zh) * 2016-12-05 2020-06-19 四川科伦博泰生物医药股份有限公司 取代的杂环化合物及其衍生物，其药物组合物、制备方法及用途
CN107383008A (zh) * 2017-08-14 2017-11-24 苏州信恩医药科技有限公司 一种罗拉匹坦的合成方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678317A (zh) * 2002-07-03 2005-10-05 先灵公司 用作治疗呕吐、抑郁症、焦虑症和咳嗽的神经激肽－1(nk－1)拮抗剂的1－酰氨基－4－苯基－4－苄氧基甲基－哌啶衍生物和相关化合物
CN1897942A (zh) * 2003-12-22 2007-01-17 先灵公司 药用组合物
CN102573475A (zh) * 2009-08-14 2012-07-11 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂

Also Published As

Publication number Publication date
US12421260B2 (en) 2025-09-23
US20220380393A1 (en) 2022-12-01
TW202115064A (zh) 2021-04-16
CN113905735A (zh) 2022-01-07
MX2021015827A (es) 2022-04-11
AU2020308397B2 (en) 2026-01-08
KR20220054287A (ko) 2022-05-02
CA3144247A1 (en) 2020-12-30
JP7702887B2 (ja) 2025-07-04
EP3991730A4 (en) 2023-08-09
TWI853965B (zh) 2024-09-01
CN118324811A (zh) 2024-07-12
BR112021026554A2 (pt) 2022-05-24
EP3991730A1 (en) 2022-05-04
JP2025111616A (ja) 2025-07-30
AU2020308397A1 (en) 2022-02-17
WO2020259675A1 (zh) 2020-12-30
JP2022539570A (ja) 2022-09-12
KR102940508B1 (ko) 2026-03-16

Similar Documents

Publication Publication Date Title
CN113905735B (zh) 神经激肽-1拮抗剂
TWI828358B (zh) 囊性纖維化跨膜傳導調節因子之調節劑、醫藥組合物、治療方法及製造該調節劑之方法
JP7083087B2 (ja) それに関連する障害の治療または予防に有用なβ－３アドレナリン受容体調節剤
IL314296B2 (en) Benzopyrimidine compounds and use thereof
EP4504699A1 (en) Complement factor b inhibitors and uses thereof
EP1161434B1 (fr) Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
TWI846774B (zh) 作為免疫調節的芳環衍生物及其製備方法和應用
KR20240004495A (ko) 이소퀴놀론 화합물과 이의 용도
TW202309020A (zh) KEAP1-Nrf2蛋白-蛋白交互作用抑制劑
CZ287071B6 (en) Galanthamine derivatives, pharmaceutical preparation containing them and use of those derivatives as medicaments
WO2020156189A1 (zh) 喜树碱衍生物及其水溶性前药、包含其的药物组合物及其制备方法和用途
TW202506108A (zh) 含多稠環結構的化合物
KR102356040B1 (ko) α7니코틴성 아세틸콜린 수용체의 리간드 화합물 및 그 응용
CN113272315A (zh) 一类类固醇化合物及其用途
HK40064843A (en) Neurokinin-1 antagonist
RU2827715C2 (ru) Антагонист нейрокинина-1
JP7227427B2 (ja) Ｓｇｌｔ２／ｄｐｐ４阻害剤及びその使用
HK40064843B (zh) 神经激肽-1拮抗剂
CA3247773C (en) Benzopyrimidine compounds and use thereof
FR2719842A1 (fr) Sels quaternaires de dérivés de 1-azabicyclo [2.2.2] octane, leur préparation et leur application en thérapeutique.
EA051840B1 (ru) Бензопиримидиновые соединения и их применение
HK40117267A (zh) 新颖咪唑并吡啶和吡唑并吡啶磺醯胺衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40064843

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220707

Address after: 361026 room 53, floor 1, building A19, Xiamen biomedical industrial park, 2036 wengjiao West Road, Haicang District, Xiamen City, Fujian Province

Applicant after: Fujian Shengdi Pharmaceutical Co.,Ltd.

Applicant after: SHANGHAI SHENGDI PHARMACEUTICAL Co.,Ltd.

Applicant after: Shanghai senhui Pharmaceutical Co.,Ltd.

Applicant after: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Address before: 201210 No. 1288, Haike Road, Zhangjiang Town, Pudong New Area, Shanghai

Applicant before: SHANGHAI SHENGDI PHARMACEUTICAL Co.,Ltd.

Applicant before: Shanghai senhui Pharmaceutical Co.,Ltd.

Applicant before: JIANGSU HENGRUI MEDICINE Co.,Ltd.

GR01 Patent grant
GR01 Patent grant